EBR:UCB 30 September 2025

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics jumped to secure $500 million through stock and pre-funded warrants Monday, following a spike in its shares after interim results from its investigational psoriasis treatment. The surge also sparked new comparisons to big-name drugs from AbbVie and UCB.

27 April 2026

EBR:UCB·NYSE:ABBV·Pharmaceutical Industry·Stock Market

Euronext After the Bell: Eurozone Stocks End Mixed as Fed Rate-Cut Bets Cap Week of Gains (December 5, 2025)

European stock markets wrapped up Friday’s session in a cautious mood, with major Euronext indices hovering near record highs but lacking the momentum to stage a full‑blown “Santa rally” ahead of next week’s pivotal U.S. Federal Reserve meeting.

5 December 2025

EBR:UCB·European Markets·Federal Reserve

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains

European markets closed the first day of the week with small gains. The pan‑European STOXX 600 edged up 0.18% to 555.53 aa.com.tr. Germany’s DAX 40 barely budged to 23,745.06 aa.com.tr, while Britain’s FTSE 100 added 0.16% to 9,299.84 aa.com.tr. France’s CAC 40 rose 0.13% to 7,880.87. By contrast, Italy’s FTSE MIB and Spain’s IBEX 35 both fell about 0.22% on the day aa.com.tr. Across the Atlantic, U.S. stock futures were little changed, reflecting caution ahead of key U.S. developments.

30 September 2025

EBR:UCB·European Markets·LSE:AZN·LSE:GSK·NYSE:CCL·Stock Market·XETRA:LHA

EBR:UCB 30 September 2025 - 27 April 2026

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Euronext After the Bell: Eurozone Stocks End Mixed as Fed Rate-Cut Bets Cap Week of Gains (December 5, 2025)

European Stocks Climb Despite Shutdown Fears – Healthcare and Luxury Lead Gains